Patents by Inventor Jacques Van Snick
Jacques Van Snick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957751Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: February 12, 2021Date of Patent: April 16, 2024Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Publication number: 20230287094Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-?3) are provided, particularly recognizing human and mouse TGF-?3, particularly antibodies and fragments that do not recognize or bind TGF-?1 or TGF-?2. Particular antibodies are provided which specifically recognize and neutralize TGF-?3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: September 23, 2022Publication date: September 14, 2023Inventors: Jacques VAN SNICK, Catherine UYTTENHOVE
-
Patent number: 11485780Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-?3) are provided, particularly recognizing human and mouse TGF-?3, particularly antibodies and fragments that do not recognize or bind TGF-?1 or TGF-?2. Particular antibodies are provided which specifically recognize and neutralize TGF-?3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.Type: GrantFiled: June 26, 2020Date of Patent: November 1, 2022Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Jacques Van Snick, Catherine Uyttenhove
-
Publication number: 20210403545Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: ApplicationFiled: February 12, 2021Publication date: December 30, 2021Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Patent number: 10947303Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: July 26, 2018Date of Patent: March 16, 2021Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH, LTD.Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Publication number: 20200392221Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-?3) are provided, particularly recognizing human and mouse TGF-?3, particularly antibodies and fragments that do not recognize or bind TGF-?1 or TGF-?2. Particular antibodies are provided which specifically recognize and neutralize TGF-?3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: June 26, 2020Publication date: December 17, 2020Inventors: Jacques VAN SNICK, Catherine UYTTENHOVE
-
Patent number: 10723793Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-?3) are provided, particularly recognizing human and mouse TGF-?3, particularly antibodies and fragments that do not recognize or bind TGF-?1 or TGF-?2. Particular antibodies are provided which specifically recognize and neutralize TGF-?3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.Type: GrantFiled: June 10, 2016Date of Patent: July 28, 2020Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Jacques Van Snick, Catherine Uyttenhove
-
Publication number: 20190160177Abstract: The present invention relates to a compound comprising one or more PEG moieties, wherein said compound is a therapeutic agent active for treating a respiratory disease. The present invention also relates to a method for preventing and/or treating a respiratory disease in a subject in need thereof comprising the administration of a PEGylated therapeutic agent. Another object of the invention is a method for enhancing the bioavailability of a therapeutic agent, for enhancing the pulmonary residency of a therapeutic agent and/or for reducing the pulmonary clearance of a therapeutic agent, wherein said methods comprise the PEGylation of the therapeutic agent.Type: ApplicationFiled: January 31, 2019Publication date: May 30, 2019Inventors: Rita VANBEVER, Salomé KOUSSOROPLIS, Didier CATALDO, Jacques VAN SNICK
-
Publication number: 20190092847Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: ApplicationFiled: July 26, 2018Publication date: March 28, 2019Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Patent number: 10035851Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: November 2, 2016Date of Patent: July 31, 2018Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Publication number: 20180148501Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-?3) are provided, particularly recognizing human and mouse TGF-?3, particularly antibodies and fragments that do not recognize or bind TGF-?1 or TGF-?2. Particular antibodies are provided which specifically recognize and neutralize TGF-?3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: June 10, 2016Publication date: May 31, 2018Inventors: Jacques VAN SNICK, Catherine UYTTENHOVE
-
Publication number: 20170137507Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: ApplicationFiled: November 2, 2016Publication date: May 18, 2017Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Patent number: 9518112Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: March 6, 2013Date of Patent: December 13, 2016Assignee: Ludwig Institute for Cancer Research LTDInventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Publication number: 20160331839Abstract: The present invention relates to a compound comprising one or more PEG moieties, wherein said compound is a therapeutic agent active for treating a respiratory disease. The present invention also relates to the use of a PEGylated therapeutic agent for treating a respiratory disease. Another object of the invention is a method for enhancing the bioavailability of a therapeutic agent, for enhancing the pulmonary residency of a therapeutic agent and/or for reducing the pulmonary clearance of a therapeutic agent, wherein said methods comprise the PEGylation of the therapeutic agent.Type: ApplicationFiled: January 16, 2015Publication date: November 17, 2016Inventors: Rita VANBEVER, Salome KOUSSOROPLIS, Didier CATALDO, Jacques VAN SNICK
-
Publication number: 20150132319Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: ApplicationFiled: March 6, 2013Publication date: May 14, 2015Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Publication number: 20080299073Abstract: The invention relates to methods for the treatment and/or prophylaxis of infections that produce an imbalance of Th1 and Th2 CD4 cells such as Leishmaniasis, via the administration of an antibody to IL-9 or an agent that stimulates production of anti-IL-9 antibodies sufficient to neutralize native IL-9 in a subject.Type: ApplicationFiled: July 27, 2005Publication date: December 4, 2008Inventors: Jacques Van Snick, Frank Brombacher, Berenice Arendse
-
Publication number: 20080299134Abstract: The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.Type: ApplicationFiled: March 17, 2008Publication date: December 4, 2008Applicants: MedImmune, Inc., Ludwig Institute for Cancer ResearchInventors: Jennifer Lynne Reed, William Dall'Acqua, Jacques Van Snick, Jean-Christophe Renauld, Francoise Cormont, Catherine Uyttenhove
-
Patent number: 7371383Abstract: The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.Type: GrantFiled: April 11, 2003Date of Patent: May 13, 2008Assignees: MedImmune, Inc., Ludwig Institute for Cancer ResearchInventors: Jennifer Lynne Reed, William Dall'Acqua, Jacques Van Snick, Jean-Christophe Renauld, Francoise Cormont, Catherine Uyttenhove
-
Publication number: 20070048261Abstract: The present invention provides improved vaccines and immunogenic compositions comprising IL-12 or IL-23, and processes for the preparation of such vaccines and immunogenic compositions.Type: ApplicationFiled: December 14, 2004Publication date: March 1, 2007Applicant: GlaxoSmithKline Biologicals S.A.Inventors: Pascal Mettens, Catherine Uyttenhove, Jacques Van Snick
-
Patent number: 7157091Abstract: The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0–10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.Type: GrantFiled: June 18, 1999Date of Patent: January 2, 2007Assignee: Ludwig Institute for Cancer ResearchInventors: Jacques Van Snick, Bernard Lethé, Pascal Chaux, Thierry Boon-Falleur, Pierre van der Bruggen